1 min read|40 words
Breaking: Global regulatory agencies are reaching conflicting decisions on new Alzheimer's treatments, creating unprecedented disparities in patient access worldwide. The Lancet examines why breakthrough drugs face such different approval pathways across countries.
Read the full article on GMJ Newsroom →
Was this article helpful?
